# Erlotinib

## Tarceva 150mg

##### 臨採

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | OTAR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Indications        | Treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least 1 prior chemotherapy regimen.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Dosing             | [Non–small cell lung cancer (NSCLC) (as first-line therapy， maintenance treatment， or for progressive disease)] 150 mg taken on an empty stomach at least 1 hour before or 2 hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Contraindications  | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | Rash， diarrhea， anorexia， fatigue， dyspnea， cough， nausea， vomiting， stomatitis， pruritus， dry skin， conjunctivitis， keratoconjunctivitis sicca， abdominal pain. Rarely， elevated liver enzymes， GI bleeding (in association with concomitant administration of warfarin or NSAIDs). Cardiovascular: Edema (37% ) Dermatologic: Alopecia (14% )， Pruritus (7.4% to 13% )， Rash， Any grade (49.2% to 75% ) Endocrine metabolic: Weight decreased (3.9% to 39% ) Gastrointestinal: Abdominal pain (11% to 46% )， Diarrhea， Any grade (20.3% to 54% )， Flatulence (13% )， Indigestion (17% )， Inflammatory disease of mucous membrane (17% to 22% )， Loss of appetite (9.2% to 52% )， Nausea (33% to 60% )， Vomiting (23% to 42% ) Hepatic: Hyperbilirubinemia， Increased liver enzymes Immunologic: Infectious disease (39% ) Musculoskeletal: Bone pain (25% )， Myalgia (21% ) Neurologic: Headache (15% ) Ophthalmic: Conjunctivitis (12% )， Keratoconjunctivitis sicca (12% ) Psychiatric: Anxiety (13% )， Depression (19% ) Respiratory: Cough (16% to 33% )， Dyspnea (24% to 41% ) Other: Fatigue (9% to 73% )， Fever (36% ) |
| Pregnancy          | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

